Press Release October 20, 2022

AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Portfolio

The Life Sciences team advised DJS Antibodies on its acquisition by AbbVie (NYSE: ABBV).

DJS Antibodies is a biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors.

The Goodwin team was led by Graham Defries and Kenny Walker-Durrant.

For more details, read the press release.